Vectura Group Services Limited develops and sells oral and inhalation pharmaceutical products worldwide. The company’s inhalation products include flutiform, an inhalation drug for asthma; and Relvar Ellipta/Breo Ellipta, Anoro Ellipta, and Incruse Ellipta, which are used for the treatment of asthma and chronic obstructive pulmonary diseases. It also offers Solaraze, a topical gel treatment for actinic keratosis; and Exparel, a bupivacaine injectable product for post-surgical pain management. The company’s oral drug delivery products comprise RAYOS/Lodotra for the treatment of morning stiffness associated with rheumatoid arthritis; Requip, which provides smoother delivery of ropinirole; Xatra/Uroxatral, an alpha blocker product; Madopar DR/ Prolopa, an oral treatment for Parkinson’s disease; Sular, a calcium channel blocker antihypertensive agent; and ZYFLO CR, an extended-release formulation of the oral asthma drug zileuton. Its oral drug delivery products also comprise Paxil CR, an anti-depressant; Diclofenacratiopharm Uno, a dual release diclofenac sodium formulation for pain/inflammation; Triglide, an oral treatment for elevated blood lipid disorders; and Coruno for the oral treatment of chronic angina pectoris. The company has partnership agreements with various companies, including Sanofi, Mundipharma, and Kyorin. Vectura Group Services Limited was formerly known as Skyepharma Limited and changed its name to Vectura Group Services Limited in June 2018. The company was founded in 1910 and is headquartered in London, the United Kingdom. As of June 10, 2016, Vectura Group Services Limited operates as a subsidiary of Vectura Group plc.